How to Help Your Patients Find Outgro Pain Relief in Stock: A Provider's Guide

Patient medication access is increasingly a part of clinical practice — not just diagnosis and prescribing. When patients can't find a medication they need, they often turn to their provider for help. If your patients are asking about Outgro Pain Relief, this guide gives you the context, practical tools, and clinical recommendations you need to help them efficiently.

Why Are Patients Having Trouble Finding Outgro?

Outgro Pain Relief (benzocaine 20% topical liquid, MedTech Products Inc.) has been discontinued from most major retail pharmacy chains. This is not an FDA-designated drug shortage — it is a retail-level discontinuation driven by several factors: the FDA's 1993-1994 finding that benzocaine is not proven effective for ingrown toenail pain (which had been Outgro's primary use), concerns about benzocaine-associated methemoglobinemia, and the emergence of FDA-approved alternatives like sodium sulfide 1% for ingrown toenail pain.

The product is not completely gone — some regional grocery chains, online retailers, and independent pharmacies still carry it — but it requires significantly more effort to locate than it did even a few years ago.

Assessing the Patient's Actual Need

Before helping a patient find Outgro specifically, ask yourself what condition they're actually treating:

Ingrown toenail pain: Outgro's benzocaine 20% is not FDA-approved for this use. Dr. Scholl's Ingrown Toenail Pain Reliever (sodium sulfide 1%) is the evidence-based OTC option. For recurrent or infected cases, refer to podiatry.

Minor foot skin irritation/chafing: Outgro's labeled use. Therapeutically equivalent alternatives (generic benzocaine 20% liquid, Dermoplast spray) are widely available.

Patient preference/familiarity: Some long-time users prefer Outgro by name. In these cases, use the locating strategies below.

Practical Strategies to Help Patients Locate Outgro

When a patient specifically needs Outgro, here are the most effective locating approaches to share with them:

Refer to medfinder — medfinder for providers is a service that calls pharmacies near the patient's location to check which ones have a medication in stock, then texts results to the patient. It covers OTC and prescription products, making it useful for hard-to-find items like Outgro.

Regional grocery store pharmacies — Chains like Hy-Vee and regional independents are more likely to carry niche OTC products than national chains. The UPC for Outgro Benzocaine Pain Relieving Liquid is 75137053110.

Online retail — Amazon and Instacart list the product with fluctuating availability. Patients comfortable with online ordering can check these platforms.

Independent pharmacies — Many independent pharmacies carry products that major chains have dropped. Encourage patients to call with the product name and UPC.

Clinical Recommendations When Outgro Is Unavailable

If Outgro is not available and the patient needs an OTC alternative:

Ingrown toenail (primary indication): Sodium sulfide 1% gel (Dr. Scholl's Ingrown Toenail Pain Reliever). This is the only FDA-approved OTC ingredient for this specific condition.

Minor skin irritation (labeled use): Generic benzocaine 20% topical liquid or Dermoplast spray (benzocaine 20% + menthol 0.5%).

Benzocaine allergy/sensitivity: LMX 4 cream (lidocaine 4%, amide-type anesthetic, OTC); longer duration and different chemical class.

Safety Screening for Benzocaine Products

Before recommending any benzocaine topical product, screen for:

Prior history of methemoglobinemia (absolute contraindication)

Known allergy to benzocaine or ester-type anesthetics

Concurrent nitrate/nitrite therapy (nitroglycerin) — increased methemoglobin risk

Pulmonary disease (asthma, COPD, emphysema), cardiac disease — increased methemoglobin risk

G6PD deficiency or pyruvate kinase deficiency — increased methemoglobin risk

Age under 2 — contraindicated

Documentation and Follow-Up

When advising patients on OTC products, document your recommendation and any counseling provided. If a patient is using benzocaine products chronically or in higher volumes, monitor for any signs of methemoglobinemia. Remind patients to stop use if the condition does not improve within 7 days or worsens, and to seek care for any signs of skin infection around the affected area.

For more clinical background, see: Outgro Pain Relief Shortage: What Providers and Prescribers Need to Know in 2026